Anti-Diabetic Drug Sales Soar In Kerala; Medicines Worth ₹ 2,000 Cr Sold In 1 Year

Kannur : Sales of anti-diabetic drugs are soaring in Kerala. Reportedly, diabetic patients in the state bought medicines, including tablets and insulin, worth ₹ 2,000 crores within one year.

As per reports, medicines worth ₹ 15,000 crores were sold on an average during the last financial year and 15 per cent accounted for diabetic medicines.

In Kerala, cardiovascular drugs occupy first position in terms of sale, while anti-diabetic drugs are second in position. Also, diabetic complications are one of the major causes of heart diseases.

According to All Kerala Chemist and Druggist Association (AKCDA), the diabetic drug sales are increasing significantly each year.

In India, there has been a total sale of medicines worth ₹ 1.76 lakh crore in the last year. There has been a rapid increase in sales since the last 10 years.

Apparently, two types of modern insulins, metformin+glimepiride, metformin+vildagliptin and metformin+sitagliptin are the top five selling drugs.

  • Related Posts

    • Pharma
    • July 10, 2025
    • 115 views
    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    India stands tall as a pharmaceutical powerhouse, supplying 20% of the world’s generic medicines and nearly 62% of global vaccines. Yet, this success now faces a storm: US President Donald…

    • Pharma
    • July 10, 2025
    • 98 views
    Novartis wins approval for first malaria drug for newborns and babies

    ZURICH: Novartis (NOVN.S), opens new tab said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat malaria in babies…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Novartis wins approval for first malaria drug for newborns and babies

    Novartis wins approval for first malaria drug for newborns and babies

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr